88 research outputs found
Beam-target helicity asymmetry for γ→n→→π−p in the N*resonance region
We report the first beam-target double-polarization asymmetries in the γ þ nðpÞ → π− þ pðpÞ reaction
spanning the nucleon resonance region from invariant mass W ¼ 1500 to 2300 MeV. Circularly polarized
photons and longitudinally polarized deuterons in solid hydrogen deuteride (HD) have been used with the
CEBAF Large Acceptance Spectrometer (CLAS) at Jefferson Lab. The exclusive final state has been
extracted using three very different analyses that show excellent agreement, and these have been used to
deduce the E polarization observable for an effective neutron target. These results have been incorporated
into new partial wave analyses and have led to significant revisions for several γnN* resonance
photocouplings
Measurement of Exclusive Electroproduction Structure Functions and their Relationship to Transversity GPDs
Exclusive electroproduction at a beam energy of 5.75 GeV has been
measured with the Jefferson Lab CLAS spectrometer. Differential cross sections
were measured at more than 1800 kinematic values in , , , and
, in the range from 1.0 to 4.6 GeV,\ up to 2 GeV,
and from 0.1 to 0.58. Structure functions and were extracted as functions of for each of
17 combinations of and . The data were compared directly with two
handbag-based calculations including both longitudinal and transversity GPDs.
Inclusion of only longitudinal GPDs very strongly underestimates and fails to account for and ,
while inclusion of transversity GPDs brings the calculations into substantially
better agreement with the data. There is very strong sensitivity to the
relative contributions of nucleon helicity flip and helicity non-flip
processes. The results confirm that exclusive electroproduction offers
direct experimental access to the transversity GPDs.Comment: 6 pages, 2 figure
Transverse Polarization of in Photoproduction on a Hydrogen Target in CLAS
Experimental results on the hyperon transverse polarization
in photoproduction on a hydrogen target using the CLAS detector at Jefferson
laboratory are presented. The was reconstructed in the
exclusive reaction via the
decay mode. The was reconstructed in the
invariant mass of two oppositely charged pions with the identified in
the missing mass of the detected final state. Experimental data
were collected in the photon energy range = 1.0-3.5 GeV
( range 1.66-2.73 GeV). We observe a large negative polarization of
up to 95%. As the mechanism of transverse polarization of hyperons produced in
unpolarized photoproduction experiments is still not well understood, these
results will help to distinguish between different theoretical models on
hyperon production and provide valuable information for the searches of missing
baryon resonances.Comment: pages 1
Cross sections for the γp→K*+Λ and γp→K*+Σ0 reactions measured at CLAS
The first high-statistics cross sections for the reactions γp→K*+Λ and γp→K*+Σ0 were measured using the CLAS detector at photon energies between threshold and 3.9 GeV at the Thomas Jefferson National Accelerator Facility. Differential cross sections are presented over the full range of the center-of-mass angles, and then fitted to Legendre polynomials to extract the total cross section. Results for the K*+Λ final state are compared with two different calculations in an isobar and a Regge model, respectively. Theoretical calculations significantly underestimate the K*+Λ total cross sections between 2.1 and 2.6 GeV, but are in better agreement with present data at higher photon energies
Deep exclusive electroproduction off the proton at CLAS
The exclusive electroproduction of above the resonance region was
studied using the Large Acceptance Spectrometer () at
Jefferson Laboratory by scattering a 6 GeV continuous electron beam off a
hydrogen target. The large acceptance and good resolution of ,
together with the high luminosity, allowed us to measure the cross section for
the process in 140 (, , ) bins:
, 1.6 GeV GeV and 0.1 GeV
GeV. For most bins, the statistical accuracy is on the order of a few
percent. Differential cross sections are compared to two theoretical models,
based either on hadronic (Regge phenomenology) or on partonic (handbag diagram)
degrees of freedom. Both can describe the gross features of the data reasonably
well, but differ strongly in their ingredients. If the handbag approach can be
validated in this kinematical region, our data contain the interesting
potential to experimentally access transversity Generalized Parton
Distributions.Comment: 18pages, 21figures,2table
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Background:
Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke.
Methods:
We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515.
Findings:
Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group.
Interpretation:
In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes.
Funding:
GlaxoSmithKline
Measurements of ep→e′π+π−p′ cross sections with CLAS at 1.40GeV <W < 2.0 GeV and 2.0 GeV2 <Q2 < 5.0 GeV2
This paper reports new exclusive cross sections for ep → ep
π+π−p' using the CLAS detector at Jefferson
Laboratory. These results are presented for the first time at photon virtualities 2.0 GeV2 < Q2 < 5.0 GeV2 in
the center-of-mass energy range 1.4 GeV <W< 2.0 GeV, which covers a large part of the nucleon resonance
region. Using a model developed for the phenomenological analysis of electroproduction data, we see strong
indications that the relative contributions from the resonant cross sections at W < 1.74 GeV increase with Q2.
These data considerably extend the kinematic reach of previous measurements. Exclusive ep → ep
π+π−p' cross
section measurements are of particular importance for the extraction of resonance electrocouplings in the mass
range above 1.6 GeV
Differential cross sections and polarization observables from CLAS K* photoproduction and the search for new N* states
The reaction gamma p --> K*+ was measured using the CLAS detector for photon energies between the threshold and 3.9 GeV at the Thomas Jefferson National Accelerator Facility. For the first time, spin-density matrix elements have been extracted for this reaction. Differential cross sections, spin density matrix elements, and the Lambda recoil polarization are compared with theoretical predictions using the BnGa partial wave analysis. The main result is the evidence for significant contributions from N(1895)1/2- and N(2100)1/2+to the reaction. Branching ratios for decays into K* Lambda for these resonances and further resonances are reported
- …